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Summary 
The possibility that adult bone marrow cells retain a remarkable degree of developmental 
plasticity and acquire the cardiomyocyte lineage after infarction has been challenged and 
the notion of bone marrow cell transdifferentiation has been questioned. The center of the 
controversy is the lack of unequivocal evidence in favor of myocardial regeneration by 
the injection of bone marrow cells in the infarcted heart. Because of the great interest in 
cell-based therapy for heart failure, several approaches including gene reporter assay, 
genetic tagging, cell genotyping, PCR-based detection of donor genes, and direct 
immunofluorescence with quantum dots were employed to document or disprove bone 
marrow cell transdifferentiation into functionally competent myocardium. Together, our 
studies indicate that locally delivered bone marrow cells generate de novo myocardium 
composed of integrated cardiomyocytes and coronary vessels. Importantly, this process 
occurs independently of cell fusion and ameliorates structurally and functionally the 
outcome of the post-infarcted heart.                 
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Introduction  
Endothelial progenitor cells, mononuclear bone marrow cells, and CD34 positive cells 
have been administered to patients affected by acute myocardial infarction or chronic 
ischemic heart failure. These interventions have had positive outcome documenting not 
only the feasibility and safety of this therapeutic approach but also beneficial effects on 
cardiac function. While patients are currently enrolled in large clinical trials, the 
mechanisms by which bone marrow progenitor cells (BMPCs) ameliorate the function of 
the infarcted heart is currently under intense debate. Additionally, the documentation of 
cardiac specific adult progenitor cells (CPCs) has created great expectation concerning 
the utilization of this new cell for the management of the human disease. Theoretically, 
the most logic and potentially powerful cell to be employed for cardiac repair is the CPC. 
It is intuitively apparent that if the adult heart possesses a pool of primitive, 
undifferentiated, multipotent cells, these cells must be tested first, before more complex 
and unknown cells are explored. The attraction of this approach is its simplicity. Cardiac 
regeneration would be accomplished by enhancing the normal turnover of myocardial 
cells. However, difficulties exist in the acquisition of myocardial samples in humans, and 
in the isolation and expansion of CPCs in quantities that can be employed therapeutically. 
Conversely, bone marrow progenitor cells (BMPCs) constitute an appealing form of cell 
intervention; BMPCs can be easily collected from bone marrow aspirates or the 
peripheral blood upon their mobilization from the bone marrow with cytokines. At 
present, it is unknown whether CPCs and BMPCs are similarly effective in reconstituting 
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dead myocardium after infarction or limitations exist in CPC growth and BMPC 
transdifferentiation resulting in inadequate restoration of lost tissue. Also, BMPCs may 
constitute a necessary initial form of intervention for the infarcted heart whereas CPCs 
might be employed later during the chronic evolution of the cardiac myopathy. Thus, a 
fundamental question to be addressed is whether BMPCs are capable of promoting 
myocardial regeneration with the formation of functionally competent myocytes and 
coronary vessels in models of ischemic heart failure.  
Cardiac repair after infarction is mediated by several factors including (a) number 
of cells to be administered, (b) cell death and survival in the hostile milieu of the infarct 
and peri-infarcted region, (c) cell engraftment, and (d) cell growth and differentiation. An 
additional critical variable of BMPCs is their level of plasticity, which is dictated by their 
ability to acquire the myocyte, and vascular smooth muscle (SMC) and endothelial cell 
(EC) lineages. Moreover, the injected BMPCs can contribute indirectly to cardiac 
regeneration by releasing a variety of peptides that exert a paracrine action on the 
myocardium and its resident progenitor cells. These mechanisms are not mutually 
exclusive and both progenitor cell populations may participate directly and indirectly in 
the repair process. In all cases, progenitor cells have to engage themselves in homing into 
the myocardium to perform specific functions. These biological processes depend on a 
successful interaction between BMPCs and tissue microenvironment.  
Importantly, the unfavorable microenvironment of the infarct varies with time and 
infarct healing. Apoptotic myocytes and vascular cells are replaced by diffuse cell 
necrosis, inflammation, and myocardial scarring. These evolving characteristics of the 
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dead myocardium may have consequences on BMPC homing, survival, growth and 
differentiation.  
Preliminary published observations indicate that the stem cell antigen c-kit is 
expressed in a population of BMPCs that are capable of differentiating into 
cardiomyocytes, SMCs and ECs restoring in part large myocardial infarcts and 
ventricular performance. Therefore, the stem cell epitope c-kit was employed to isolate 
progenitor cells from the bone marrow and the cells were injected locally within the 
myocardium bordering the infarct. Although this approach allowed us to obtain a 
reasonably homogeneous preparation of progenitor cells, it has limitations related to the 
uncommitted or early committed state of the cells, their quiescent or cycling condition, 
and their migratory properties. However, the collection of progenitor cell classes by stem 
cell antigens remains the most reasonable and sensitive strategy to date. 
The mechanisms that guide stem cell homing in the myocardium are not 
completely understood. Cardiac injury may be necessary for migration and long-term 
engraftment of stem cells in the myocardium. In the absence of tissue damage, the 
implanted stem cells are at growth disadvantage with respect to the endogenous stem 
cells. The ischemic myocardium provides a microenvironment that is particularly rich in 
cytokines favoring seeding, survival and growth of progenitor cells. The binding of SDF-
1 to its receptor CXCR4 is critical in promoting homing of BMPCs to the bone marrow 
and distant organs, although IGF-1 and HGF may be crucial in opposing death signals 
and facilitating migration, respectively. SDF-1, IGF-1, and HGF are upregulated in the 
border zone acutely after infarction and may enhance BMPC viability, translocation and 
homing. Engraftment of BMPCs necessitates the formation of adherens and gap junctions 
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with resident myocytes and fibroblasts, which are the supporting cells in the niches and 
anchor the injected cells to the host myocardium. Interaction between integrin receptors 
on progenitor cells and extracellular matrix proteins is fundamental for cell lodging, 
division, and maturation. BMPCs colonize the heart and might possess a high degree of 
plasticity adapting rapidly their phenotype to the cardiac microenvironment. The process 
of transdifferentiation may alter the growth behavior of BMPCs, which may lose in part 
their ability to divide after the acquisition of the myocyte phenotype. Similarly, myocytes 
derived from BMPCs may possess inherent limitations in the acquisition of the adult 
phenotype. However, the opposite may also be true and BMPCs may retain even after 
transdifferentiation a strong regenerative capacity representing an appropriate cell for the 
damaged heart. Thus, the growth properties of BMPCs and derived myocytes were 
established to resolve this biologically and clinically relevant issue.      
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 Bone Marrow Cells and Cardiac Repair 
To date, the hematopoietic stem cell appears to be the most versatile stem cell in crossing 
lineage boundaries and the most prone to break the law of tissue fidelity1,2. Early studies 
on bone marrow cell (BMC) differentiation into myocardium have generated great 
enthusiasm3-5 but other observations have rejected the initial positive results6-8 and 
promoted a wave of skepticism about the therapeutic potential of BMCs for the injured 
heart9. The major criticisms include inaccurate interpretation of the original data due to 
autofluorescence artifacts and the lack of genetic markers for the recognition of the donor 
BMCs and their progeny6-9. In fact, the apparent improvement in function of the infarcted 
heart observed following BMC administration was assumed to be mediated by 
unidentified paracrine effects exerted by the delivered cells on the surviving 
myocardium10.  
In an attempt to address these critical issues, female infarcted mice were injected 
with male EGFP-positive c-kit-positive BMCs (c-kit-BMCs) and the consequences of this 
intervention on post-infarction remodeling were determined 5, 10 and 30 days later. 
Additionally, another set of experiments was conducted in which donor c-kit-BMCs were 
obtained from male mice carrying EGFP or a c-myc-tagged nuclear Akt transgene under 
the control of the cardiac specific α-myosin-heavy-chain promoter11. Similarly, the 
efficacy of this protocol on the post-infarcted heart was evaluated 5, 10 and 30 days after 
treatment. These three models allowed us to determine the destiny of c-kit-BMCs within 
the recipient heart by genetic tagging with EGFP, cell fate tracking with EGFP and c-
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myc, sex-chromosome identification by in situ hybridization, EGFP and c-myc gene 
detection by PCR.  
An essential premise of these studies was the development of a methodology in 
which immunolabeling of proteins was obtained in the absence of the autofluorescence 
inherent in tissue sections of formalin-fixed myocardium. This objective was achieved by 
implementing a new technology by which primary antibodies are directly labeled by 
small semi-conductor particles termed quantum dots12. This procedure eliminates the 
needs for secondary antibody staining and avoids the interference of autofluorescence in 
the specificity of the reaction. The excitation wavelength of quantum dots is widely 
separated from the emission wavelength and the spectrum of autofluorescence never 
coincides with the emission wavelength (Fig. 1a-d). Moreover, myocardial components 
labeled by antibodies conjugated with quantum dots preserve fluorescence intensity and 
do not experience a time-dependent fluorescence decay commonly encountered with 
standard fluorochromes such as rhodamine or fluorescein. Quantum dots are resistant to 
photobleaching and samples can be examined for extended periods by confocal or 
epifluorescence microscopy without altering the intensity of labeling or the resolution of 
the labeled structures (Fig. 1e-h).  
Engraftment of BMCs 
Given the question whether BMCs transdifferentiate into the cardiogenic lineage, donor 
male c-kit-BMCs were obtained from EGFP transgenic mice or from transgenic mice 
which carried a cardiac specific EGFP or a c-myc-tagged nuclear Akt. The male c-kit-
BMCs were then injected acutely after infarction in female wild-type mice. Within 12-36 
hours, male c-kit-BMCs engrafted within the viable myocardium bordering the infarct 
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through the formation of junctional and adhesion complexes with adjacent myocytes and 
fibroblasts (Fig. 2a, b). Myocytes and fibroblasts function as supporting cells within the 
cardiac stem cell niches13 and c-kit-BMCs have to form temporary niches within the host 
myocardium to home, survive and grow in this unfamiliar environment14. By this 
mechanism, the engrafted cells can then exert a regenerative effect, a paracrine effect, or 
both15. In the absence of cell homing, c-kit-BMCs die by apoptosis (not shown). This 
peculiar aspect of cell death is termed anoikis and is triggered by the lack of cell-to-cell 
contact16. Apoptosis was restricted to the non-engrafted c-kit-BMCs which failed to 
express connexin 43 and N-cadherin and were unsuccessful to take residence within the 
myocardium. Cell death never occurred in engrafted c-kit-BMCs. At this early time point, 
c-kit-BMCs were frequently CD45 positive. A subset of c-kit-BMCs was CD45 negative 
and expressed the cardiac transcription factors GATA4 and Nkx2.5 (Fig. 2c). Thus, c-kit-
BMCs home to the myocardium where they largely maintain the hematopoietic 
phenotype, although a small fraction of cells acquire rapidly the cardiomyocyte lineage.  
Within 2-5 days, EGFP-positive and EGFP-negative c-kit-BMCs integrated 
within the host myocardium and assembled in temporary niches, which mimicked the 
cardiac niches13. Clusters of male c-kit-BMCs and male c-kit-BMCs early committed to 
the cardiac cell lineages were found in the myocardial interstitium. The synthesis of the 
gap junction channel protein connexin 43 and the calcium dependent transmembrane 
adhesion molecule N-cadherin was critical in the phenotypic conversion of c-kit-BMCs 
into cardiac progenitor cells. Connexin 43 and N-cadherin established direct 
communications between male c-kit-BMCs, and between male c-kit-BMCs and recipient 
female myocytes and fibroblasts (Fig. 2d), and this phenomenon was invariably 
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associated with the loss of bone marrow specification with lack of expression of CD45. 
Conversely, markers of cardiomyocytes and vascular endothelial cells (ECs) and smooth 
muscle cells (SMCs) were detected in some of the engrafted male c-kit-BMCs, 
suggesting that the myocardial microenvironment changed the fate of c-kit-BMCs. 
Additionally, homed cells were cycling with a 51% cumulative BrdU labeling over a 
period of 5 days, and a 11% expression of Ki67 at this time point. Non-engrafted male 
CD45-positive c-kit-BMCs died by apoptosis and were hardly detectable at 5 days after 
implantation. Thus, c-kit-BMCs engraft, survive and grow within the myocardium by 
forming junctional complexes among them and with resident myocytes and fibroblasts. 
Gap junctions and destiny of BMCs      
An important question concerns the role that the formation of gap junctions between c-
kit-BMCs and myocytes may have in the fate of BMCs. In fact, the translocation of 
calcium from myocytes to c-kit-BMCs via gap junctions could have profound effects on 
their acquisition of the myocyte lineage, growth and differentiation. For this purpose, a 
functional assay was performed in which cell coupling was analyzed in vitro by two-
photon microscopy after preincubation and loading of c-kit-BMCs with the red 
fluorescent dye DiI, which integrates stably within the cell membrane17. Labeled c-kit-
BMCs (red) were plated with rat neonatal myocytes, which were loaded with the 
fluorescent dye calcein18. The appearance of green fluorescence in c-kit-BMCs indicated 
the transfer of calcein from myocytes to these cells mediated by the expression of 
connexin 43 and the formation of gap junctions (Fig. 3a-c). For real time dye transfer, 
cascade blue was injected either in myocytes or c-kit-BMCs and the timing of the transfer 
of fluorescence from one cell to the other was established (Fig. 3d-n).  When c-kit-BMCs 
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were loaded with rhodamine-labeled dextran, this high molecular weight dye (M.W. 
70,000) did not translocate to myocytes suggesting that the transfer of calcein occurred 
through gap junctions (Fig. 3o).       
Myocardial regeneration and BMCs                                     
Three classes of c-kit-BMCs were employed to induce myocardial regeneration: 1. Male 
EGFP-positive c-kit-BMCs from mice in which EGFP was under the control of the 
ubiquitous beta-actin promoter; 2. Male EGFP-negative c-kit-BMCs from mice in which 
EGFP was under the control of the α-myosin-heavy-chain promoter, and 3. Male EGFP-
negative c-kit-BMCs from mice in which nuclear targeted Akt had a c-myc tag and was 
under the control of the α-myosin-heavy-chain promoter. Therefore, all cells generated 
by the differentiation of the first category of c-kit-BMCs had to express EGFP while, in 
the second case, only the myocytes derived from the commitment of the c-kit-BMCs 
would acquire EGFP. And in the third instance, the c-myc tag would be equally restricted 
to the myocytes formed by transdifferentiation of c-kit-BMCs11. Male cells were 
delivered to female infarcted mice so that cell genotyping would also allow the 
distinction between endogenous resident cells and cells formed from differentiation of 
donor BMCs. 
The engraftment into the myocardium of BMCs shortly after their delivery was 
followed by a significant degree of myocardial growth within the infarct that expanded 
progressively from 5 to 10 and 30 days after cell implantation (Fig. 4a-c). The band of 
regenerated myocardium was invariably located within the mid-portion of the infarcted 
ventricle and its presence had two critical positive consequences on cardiac remodeling; 
it markedly attenuated the inflammatory response associated with the acute-subacute 
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evolution of the infarct at 5-10 days and it prevented largely scar formation with infarct 
healing at 30 days. At the three time points, the myocytes and vascular ECs and SMCs 
located within the band of newly formed myocardium expressed the different transgenes 
in the anticipated fashion. The BMCs obtained from EGFP transgenic mice generated a 
myocardium in which cardiomyocytes, ECs and SMCs were mostly EGFP-positive. 
When EGFP or the c-myc tag was regulated by α-myosin-heavy-chain, the transgenes 
were detected exclusively in myocytes (Fig. 4d-f). The recognition of the Y-
chromosome, however, allowed us to document that the vascular structures were also the 
result of BMC transdifferentiation (Fig. 4g). Because BrdU was injected daily, most of 
the new myocytes and coronary resistance arterioles and capillary profiles were labeled 
by BrdU, confirming their formation after the injection of c-kit-BMCs.  
Further documentation of the bone marrow origin of the regenerated myocardium 
was obtained by the detection of DNA sequences of EGFP and c-myc by PCR in mice 
treated with BMCs isolated from animals in which EGFP was regulated by the β-actin 
promoter or from mice where EGFP and c-myc were placed under the control of the α-
myosin heavy chain promoter. Genomic DNA was extracted from the regenerated 
infarcted myocardium and bands of expected molecular weight were identified and 
sequenced (Fig. 4h-m). Thus, adult c-kit-BMCs retain a high level of developmental 
plasticity; they acquire the cardiomyogenic and coronary vascular lineages and regenerate 
infarcted myocardium.  
Myocytes and BMCs   
In all cases, the regenerated myocardium contained new myocytes that expressed 
GATA4, Nkx2.5, MEF2C, α-sarcomeric actin, troponin I, α-actinin, and desmin. 
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Connexin 43 and N-cadherin that are the junctional proteins responsible for electrical and 
mechanical coupling were present at 5 days, but were more apparent at 10 and 30 days 
(Fig. 4e). The presence of EGFP, c-myc, and Y-chromosome offered the unequivocal 
documentation of the origin of these myocytes from the BMCs. The new myocytes were 
predominantly mononucleated with a small fraction of binucleated cells. The proportion 
of binucleated myocytes increased at one month (Fig. 5a) but was still significantly lower 
than that present in the adult myocardium; resident myocytes were ~95% binucleated and 
~4% mononucleated, which is typical of the mouse heart19. Only one X- and one Y-
chromosome were found in the new myocytes whereas the survived myocytes possessed 
two X-chromosomes. Additionally, EGFP-positive myocytes derived from EGFP-
negative BMCs were isolated and shown to possess contractile activity (Fig. 5b-f). These 
observations documented that BMC transdifferentiation resulted in the generation of 
myocytes which were functionally competent and contributed to ventricular performance.  
Additionally, the differentiation of BMCs into myocytes was assessed by the 
changes in mRNA and protein levels of EGFP and c-myc by real-time RT-PCR and 
Western blotting, respectively. In these cases, the analysis was performed in mice treated 
with BMCs isolated from animals in which EGFP and c-myc were modulated by the α-
myosin heavy chain promoter. Because of this promoter, the expression of the two 
transgenes paralleled the expression of the contractile protein α-myosin heavy chain. The 
EGFP transcript was expressed at 5, 10 and 30 days after infarction, documenting that 
BMC-derived cardiomyocytes were present at all time-points (Fig. 5g). The RT-PCR 
products had the expected molecular weight their nucleotide sequences demonstrated the 
specificity of the assay (Supplementary Fig. 5h). Similarly, the presence of the EGFP 
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and c-myc proteins was detected in the infarcted-regenerated myocardium of treated 
animals at all time intervals (Fig. 5i). Thus, BMCs defeat lineage fidelity and adopt the 
myogenic fate in the absence of cell fusion creating a chimeric heart composed of male 
and female parenchymal cells.  
Paracrine effects of BMCs 
The possibility that c-kit-BMCs do not transdifferentiate but lead to an improvement in 
ventricular function after infarction by activating the growth and differentiation of 
resident CPCs or by inducing angiogenesis through the recruitment of circulating BMCs 
has repeatedly been suggested20,21. However, with some exceptions5, the actual 
documentation of this interesting hypothesis has been elusive. Whether this paracrine 
effect is exerted by circulating BMCs that home to the myocardium or by BMCs directly 
injected within the heart, cells have to engraft and form junctional complexes with the 
recipient organ and its cellular compartments before any function can be promoted14,15. 
As shown here, c-kit-BMCs locally delivered to the border zone of the infarcted heart 
generate temporary niches and subsequently create de novo myocardium. Therefore, we 
tested whether the formation of resident female myocytes and coronary vessels within the 
surviving female myocardium was increased in the region bordering and remote from the 
infarct. Since BrdU was given to the animals throughout the experimental periods, newly 
formed structures generated by the stimulation of endogenous mechanisms had to be 
female in origin, positive for BrdU and negative for EGFP and c-myc.  
 The three classes of c-kit-BMCs had similar effects on the surviving myocardium 
of the infarcted heart. In all cases, newly formed myocytes and coronary capillaries were 
found in the adjacent and distant myocardium but the extent of myocyte and vessel 
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formation was comparable to that measured in untreated infarcted mice at 5, 10 and 30 
days after coronary occlusion (Fig. 6a). Moreover, the degree of cell replication at 
sacrifice was determined in these two anatomical regions by Ki67 and MCM5 labeling. 
Again, comparable values were obtained in cell-treated and untreated infarcted mice (Fig. 
6b and 6c). Thus, our observations are not consistent with a paracrine effect of BMCs on 
resident CPCs, myocytes or coronary vessels after infarction.                   
Ventricular function and BMCs  
An important issue to be resolved concerned whether treatment with BMCs has beneficial 
effects on the anatomy and function of the infarcted ventricle. Ventricular dilation and 
wall thinning that typically develop with ischemic heart failure are major determinants of 
the increase in ventricular loading and the deterioration of cardiac performance after 
infarction22,23. In comparison with untreated mice, the three groups of mice which 
received c-kit-BMCs, showed a smaller increase in left ventricular diastolic chamber 
diameter (LVCD) and volume (LVCV), and a smaller decrease in infarct thickness, wall 
thickness-to-chamber radius ratio and ventricular mass-to-chamber volume ratio at 30 
days (Fig. 6d).  
Importantly, sequential echocardiographic analysis documented that myocardial 
regeneration restored contractile function in the infarcted portion of the wall (Fig. 6e). 
Hemodynamic measurements at sacrifice indicated that in treated infarcted mice cardiac 
repair was associated with an increase in developed pressure and + and – dP/dt at 30 days 
(Fig. 6f). Thus, BMC treatment restores a noticeable level of contraction in the 
regenerated myocardium increasing ventricular performance.  
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 Discussion 
The results of the current study indicate that a category of adult cells from the bone 
marrow shares the kind of developmental plasticity commonly seen in embryonic stem 
cells; c-kit-BMCs engraft in proximity of the damaged area of the heart and differentiate 
into cells of the cardiogenic lineage forming a functionally competent myocardium 
composed of myocytes and coronary vessels. The regenerated myocardium positively 
interferes with the development of the post-infarction myopathy, attenuating the dramatic 
changes in ventricular size and shape and the progressive deterioration in cardiac function 
which occur chronically after infarction22,23. Our data strongly suggest that adult c-kit-
BMCs integrate within the host myocardium where they establish temporary niches 
which create the microenvironment necessary for the engrafted cells to acquire the 
cardiac fate and subsequently form de novo myocardium. These observations are 
particularly important because small double blind multi-center clinical trials in which 
mononuclear BMCs have been administered to patients with acute and chronic ischemic 
heart failure have recently been completed24,25. In spite of the positive results, the 
mechanism by which mononuclear BMCs improve the outcome of acute myocardial 
infarction and chronic ischemic cardiomyopathy in humans remains unclear. Moreover, 
effort is being made to initiate large trials regardless of the uncertainties about the actual 
effects of mononuclear BMCs on the decompensated heart. However, our results suggest 
that myocardial regeneration is a likely possibility.  
 The local injection of BMCs from transgenic mice, in which the transgene 
construct EGFP or c-myc was myocyte restricted, led to a time dependent increase in the 
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generation of myocytes and vascular structures. Thus, BMCs homed to the myocardium 
where they lost the hematopoietic fate and adopted the cardiac destiny forming new 
myocytes which participated in ventricular function. Together, the present results suggest 
that progenitor cells resident in the bone marrow and in the heart share a core of 
“stemness” genes that regulate their undifferentiated state and self-renewal properties. 
But each progenitor cell class expresses tissue-restricted genes that may determine the 
efficiency of differentiation into organ specific lineages.        
The early studies on BMCs and cardiac repair3 have been followed by numerous 
negative reports which have rejected the notion of stem cell plasticity and the relevance 
of BMCs for the management of the human disease6-9. The therapeutic potential of BMCs 
was questioned at multiple levels and the possibility of cell fusion was introduced as the 
actual mechanism of tissue repair26,27. The documentation that BMCs fuse with resident 
cardiomyocytes is technically demanding. This involves the identity of the fused cell, the 
functional competence of the progeny, the recognition of the fusion partner and the 
demonstration that the converted cell is a hybrid28. The fate of BMCs following their 
injection in injured organs has been characterized with the Cre-Lox genetic system. 
Unfortunately, the Cre-Lox model cannot exclude that metabolic cooperation occurs 
between the progenitor cell carrying the Cre-recombinase and the recipient cardiac cell. 
Because of the small molecular weight of the Cre-recombinase, this enzyme can 
translocate via gap junction channels29 or nanotubules30 to the resident cells mimicking 
cell fusion28. Therefore, we have excluded cell fusion by measuring the number of sex 
chromosomes in the preexisting and newly formed cells by the FISH assay. The new 
cardiomyocytes were functionally competent and were significantly smaller than the host 
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cells further excluding fusion events. In this regard, no viable partner cells are available 
for fusion in transmural myocardial infarcts. Importantly, fusion history may be 
concealed by the occurrence of reductive mitosis31 in which the fused cell would expel 
part of its chromosomal DNA and convert a tetraploid cell into a diploid cell, masking the 
formation of a heterokaryon. However, there is no demonstration of this unusual cell 
behavior either in vitro or in vivo. 
More recently, the possibility that BMC therapy of the infarcted heart exerts its 
beneficial effects by the activation of resident progenitor cells located in the surviving 
myocardium has been claimed10. According to this hypothesis, BMCs may contribute 
indirectly to cardiac regeneration by releasing a variety of peptides that exert a paracrine 
action on the myocardium and its resident progenitor cells. Although the current work 
does not support this indirect role of BMCs in cardiac repair, positive and negative results 
have been obtained5,20,21,32. The most convincing example in favor of the paracrine effect 
of hematopoietic cells has been found with a novel human bone marrow stem cell5. This 
unique primitive cell induces the formation of myocytes and coronary vessels within the 
infarcted heart and promotes a robust regenerative response in the surviving myocardium. 
Thus, these findings point to the notion that BMCs adopt the cardiac phenotype and 
potentiate the growth reserve of the adult heart. Collectively, these observations 
emphasize the therapeutic import of BMCs for cardiac diseases in humans.    
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Legends to Figures 
Figure 1. Autofluorescence and quantum dots. a, The excitation and emission 
wavelengths of the semiconductor particles Qdot 655 are distinct from the 
autofluorescence wavelength of tissue sections. The dotted line indicates the excitation 
wavelength for blue diode laser and Qdots, 405 nm, and the red line shows the emission 
wavelength of Qdot 655. The black line illustrates the spectrum of autofluorescence for 
formalin-fixed tissue sections. b-d, The confocal image illustrated in panels b was 
acquired with an emission wavelength of 525 nm while those shown in panels c and d 
were obtained with an emission wavelength of 655 nm. Nuclei in panel b-d are stained by 
DAPI which binds directly to DNA and does not require antibody labeling. 
Autofluorescence is detected only at 525 nm (b, green) while it is not present at 655 nm 
(c). The same field is shown in panel d after immunolabeling with α-sarcomeric actin 
(red) antibody conjugated with Qdot 655. e-h, TRITC fluorescence undergoes rapidly 
photobleaching as documented by the decay in the intensity of the signal after 10 minutes 
of exposure to the laser light of the confocal microscope (e, f). Quantum dots are resistant 
to photobleaching; intensity of labeling and structural detail is preserved after 10 minutes 
(g, h).  
Figure 2. BMCs from EGFP transgenic mice form niches in the infarcted 
myocardium. a, b, One day after infarction and injection of c-kit-positive-BMCs, the 
implanted cells engraft within the myocardium and are connected to myocytes (red, α-
sarcomeric actin) and fibroblasts (magenta, procollagen) by connexin 43 (a, yellow, 
arrowheads) and N-cadherin (b, yellow, arrowheads). BMCs express EGFP (green). c, 
BMCs that undergo myocyte differentiation lose the pan-leukocyte marker CD45 (white, 
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arrows) and express Nkx2.5 (magenta dots, arrowheads). d, Five days after myocardial 
infarction, the engrafted BMCs express c-kit (green) and form temporary niches; gap 
junctions (connexin 43, yellow, arrowheads) are apparent between myocytes (red, α-
sarcomeric actin) and fibroblasts (magenta, procollagen) and the c-kit-positive-BMCs. c-
kit-BMCs have a male genotype (Y-chromosome, white dots, arrows).     
Figure 3. c-kit-BMCs are functionally connected with cardiomyocytes. a-c, These 
images were obtained by two-photon microscopy. Sorted c-kit-positive BMCs were 
loaded with DiI (a, red fluorescence) and cocultured with neonatal myocytes labeled with 
calcein (b, green fluorescence). The appearance of green-fluorescence in c-kit-BMCs (c, 
yellow-green fluorescence, arrowheads) demonstrates the translocation of calcein from 
myocytes to c-kit-BMCs. d-o, These images were obtained by epifluorescence (d, f-j, l-o) 
and phase-contrast microscopy (e, k). EGFP-positive c-kit-BMCs (d, j, green) were co-
cultured with neonatal rat myocytes (e, k, dotted lines) and impaled with a micropipette 
filled with cascade blue (f, l, arrows). Images represent the real-time transfer of cascade 
blue from c-kit-BMCs to myocytes. Note the appearance of the fluorescent dye in the 
myocytes adjacent to the c-kit-BMCs (h, i, n, dotted lines). Red fluorescence in o depicts 
the lack of translocation of rhodamine-labeled dextran from the c-kit-BMC to the 
adjacent myocyte.  
Figure 4. Myocardial regeneration after infarction is mediated by the injection of c-
kit-BMCs. a-c, Areas of regenerated myocardium within the infarcted left ventricular 
wall, included between the epimyocardium (EP) and the endomyocardium (EN) at 5 (a), 
10 (b) and 30 (c) days after coronary occlusion. The presence of c-myc (green) in the 
newly formed myocytes (red, α-sarcomeric actin) documents their bone marrow origin. 
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Arrowheads delimit the areas of regenerated myocardium. d, Myocardium of α-MHC-
nuc-Akt mouse was employed as positive control for c-myc staining (green); only 
myocyte nuclei express the c-myc tag (arrowheads). e-g, These higher magnifications 
illustrate newly formed myocytes carrying the c-myc tag (e, f, green) or the Y-
chromosome (g, white dots in nuclei).  New myocytes are connected by gap junctions (e, 
connexin 43, yellow dots; arrowheads). Two newly formed arterioles are also evident in 
the regenerated myocardium (f, g). Smooth muscle cells express α-smooth muscle actin 
(f, g, yellow) and Y-chromosome (g, white dots). Newly formed myocytes and smooth 
muscle cells (g) contain at most one X- (green) and one Y-chromosome (white). The 
periphery of the cells is defined by laminin (d-f, white). 
h-j, Detection of mouse DNA for EGFP and c-myc in the regenerated infarcted 
myocardium (MI) and surviving myocardium (SM) of hearts injected with c-kit-BMCs 
obtained from β-actin-EGFP (h), αMHC-EGFP (i) and αMHC-nuc-Akt (j) transgenic 
mice. DNA extracted from the tails of the three transgenic animals was employed as 
positive control (+). WT, wild type mouse. LB, lysis buffer incubated with primers in the 
absence of DNA template. k-m, The nucleotide sequences of the PCR products was 
established in the sense and antisense direction to confirm the specificity of the amplified 
bands. NLS, nuclear localization signal.    
Figure 5. The regenerated myocytes are functionally competent. a, Only small 
fractions of regenerated myocytes were binucleated. Results are mean±SD. *Indicates a 
difference vs 5 and 10 days. b-f, Myocytes were isolated from the infarcted-regenerated 
myocardium 15 days after the injection of c-kit-BMCs from αMHC-EGFP transgenic 
mice. Newly formed myocytes are EGFP-positive while surviving myocytes are EGFP-
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negative (b, c). d, Phase contrast image of a contracting myocyte. Cell shortening is 
shown in panel e by EGFP fluorescence and in panel f by changes in myocyte length.  
Figure 6. Myocardial regeneration, cardiac anatomy and function. a-c, Myocyte and 
endothelial cell (EC) proliferation in the surviving myocardium of untreated (UN) and 
treated (TR) mice. The values in the three groups of treated mice were similar and were 
combined. Results are mean±SD. d, Effects of myocardial regeneration on the anatomy 
of the infarcted heart. Results are mean±SD. *Indicates a difference vs sham-operated 
mice (SO) and **indicates a difference vs untreated mice (UN). TR, treated mice. e, The 
echocardiogram shows the lack of contraction in the infarcted region of the wall of an 
untreated heart (arrows) and the reappearance of contraction (arrowheads) in the infarcted 
wall of a heart treated with c-kit-BMCs obtained from αMHC-nuc-Akt transgenic mice. 
The mid panel and lower panel correspond to the same heart analyzed at 16 and 30 days 
after cell injection, respectively. f, Effects of myocardial regeneration on the function of 
the infarcted heart. Results are mean±SD. *Indicates a difference vs sham-operated mice 
(SO) and **indicates a difference vs untreated mice (UN). TR, treated mice. g, 
Expression of EGFP mRNA in the infarcted-regenerated myocardium of treated mice by 
quantitative RT-PCR. h, Nucleotide sequences in sense and antisense directions of the 
RT-PCR products. i, Expression of EGFP and c-myc proteins in the infarcted-regenerated 
myocardium of treated mice by Western blotting. The hearts of wild type and transgenic 
mice were used as negative and positive controls, respectively.    
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Methods 
In vivo studies 
Isolation of bone marrow cells (BMCs). Three transgenic mouse models were 
employed as donors of c-kit-positive BMCs (c-kit-BMCs): male mice expressing EGFP 
under the control of the ubiquitous β-actin promoter (β-actin-EGFP); male mice 
expressing EGFP under the control of the α-myosin heavy chain promoter (αMHC-
EGFP); and male mice in which nuclear targeted Akt fused with a c-myc tag was placed 
under the control of the α-myosin heavy chain promoter (αMHC-nuc-Akt). Bone marrow 
was harvested from the femurs and tibias and cells were suspended in PBS containing 5% 
fetal calf serum. BMCs were then incubated with a CD117 microbeads and enriched for 
c-kit1 by immunomagnetic cell sorting (Miltenyi Biotec). For intramyocardial injection, 
freshly isolated c-kit-BMCs were suspended at a concentration of 6 x 104 cells in 6 µl 
PBS containing polystyrene microspheres conjugated with rhodamine (Molecular Probes) 
for the recognition of the site of injection1,2.  
Myocardial infarction 
Myocardial infarction was induced in anesthetized (ketamine 150 mg/kg body weight, 
acepromazine 0.85 mg/kg body weight) female wild type mice at ~3 months of age as 
previously described1-4.  Because of differences in the genetic background of the donors, 
c-kit-BMCs from β-actin-EGFP mice were injected in C57BL/6 mice while c-kit-BMCs 
from αMHC-EGFP and αMHC-nuc-Akt were injected in FVB/N mice. Shortly after 
coronary occlusion, two injections each of 3.0 µl of PBS containing 30,000 c-kit-BMCs 
were performed in the anterior and posterior aspects of the viable myocardium bordering 
the infarct. After the collection of hemodynamic data, mice were sacrificed at 12-36 
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hours, and at 2, 5, 10 and 30 days after surgery. Sham-operated and infarcted mice 
injected with PBS or glutaraldehyde-fixed c-kit-BMCs and rhodamine particles were 
used as controls. Additionally, all animals were injected twice a day with BrdU, 50 
mg/kg body weight intraperitoneally. Animal protocols were approved by the 
Institutional Review Board.    
Echocardiography and ventricular function. Echocardiographic parameters were 
collected in conscious mice at 10 and 30 days after infarction by using a Sequoia 256c 
(Acuson) equipped with a 13-MHz linear transducer (15L8). The anterior chest area was 
shaved and two- dimensional (2D) images and M-mode tracings were recorded from the 
parasternal short axis view at the level of papillary muscles. From M-mode tracings, 
anatomical parameters in diastole and systole were obtained1,2,4,5. Before sacrifice, mice 
were anesthetized with chloral hydrate (400 mg/kg body weight, i.p.), and a microtip 
pressure transducer (SPR-671; Millar Instruments) connected to a recorder (iWorx214) 
was advanced into the LV for the evaluation of LV pressures and LV + and  dP/dt in the 
closed-chest preparation1-5. 
Cardiac anatomy and infarct size. After hemodynamic measurements, the abdominal 
aorta was cannulated with a polyethylene catheter filled with phosphate buffer, 0.2 M, pH 
7.4, and heparin, 100 units/ml. In rapid succession, the heart was arrested in diastole by 
the injection of CdCl2, 100 mM, through the aortic catheter, the thorax opened, perfusion 
with phosphate buffer started and the vena cava cut to allow drainage of blood and 
perfusate1-5. The aortic catheter was connected to a pressure reservoir to adjust perfusion 
pressure to mean arterial blood pressure measured in vivo. Simultaneously, the LV 
chamber was filled with fixative, 10% formalin in phosphate buffer, from a pressure 
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reservoir set at a height equivalent to end-diastolic pressure determined in vivo. This was 
accomplished by inserting a 25G3/4 needle connected to the pressure reservoir into the 
LV through the apex. After perfusion with buffer for 2 min, the coronary vasculature was 
perfused for 15 min with fixative. Subsequently, the heart was excised and weights 
recorded. The volume of the myocardium was determined6 by dividing the weight by the 
specific gravity of muscle tissue, 1.06 g/ml. After paraffin embedding, three tissue 
sections, from the base to the apex of the left ventricle, were stained with hematoxylin 
and eosin. The mid-section was used to measure LV thickness, chamber diameter, and 
volume1-6. Infarct size was assessed by the fraction of myocytes lost from the LV1-6.  
Regenerated myocardium. The newly formed myocardium within the infarcted heart 
was identified by the detection of EGFP in animals injected with c-kit-BMCs from β-
actin-EGFP mice. However, in animals treated with c-kit-BMCs from αMHC-EGFP and 
αMHC-nuc-Akt mice, both EGFP and c-myc were restricted to myocytes. Therefore, the 
detection of the Y-chromosome was employed to recognize not only myocytes but also 
vascular endothelial cells (ECs) and smooth muscle cells (SMCs).  
Cell differentiation, proliferation and death. For the recognition of cell differentiation, 
the expression of membrane, cytoplasmic and nuclear proteins specific of myocytes, ECs 
and SMCs were evaluated. Labeling by BrdU, Ki67 and MCM5 was employed to 
evaluate cycling cells while apoptosis was determined by the TdT assay7-9. These 
measurements were obtained by confocal microscopy and the antibodies employed and 
the modalities of labeling are listed in Table 1.  
X and Y chromosomes. For the FISH assay1,8,9, sections were exposed to a denaturating 
solution containing 70% formamide. After dehydration with ethanol, sections were 
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hybridized with the mouse Whole Chromosome-Specific Probes for Y and X-
chromosomes (Cambio). Nuclei were stained with propidium iodide.  
PCR for detection of EGFP and c-myc DNA. This DNA analysis was performed in the 
three groups of infarcted mice treated with c-kit-BMCs obtained from β-actin-EGFP, 
αMHC-EGFP and αMHC-nuc-Akt mice. Tissue sections, in which myocardial 
regeneration was detected by immunohistochemistry, were subjected to deparaffinization 
for 30 min at 70°C and subsequently were immersed in xylene and ethanol at decreasing 
concentration. Slides were then washed in distilled water. The regenerated infarcted 
myocardium and the surviving myocardium were removed from the slides and genomic 
DNA was extracted with the QIAamp DNA micro kit (Qiagen). DNA, 100 ng, was mixed 
with primers for EGFP or c-myc. For EGFP, eGFP-F: 5'-ATGGTGAGCAAGGGCGAG-
GAGCTG-3' and eGFP-R:5'-GCCGTCGTCCTTGAAGAAGATGGTG-3' were used. 
Cycling conditions were as follows: 94°C for 30 sec, followed by 30 cycles of 
amplification (94°C for 30 sec, 62°C for 30 sec, 72°C for 30 sec), with a final incubation 
at 72°C for 3 min. For c-myc, we employed a reverse primer complementary to the c-myc 
sequence and a forward primer complementary to the adjacent Akt sequence: c-myc-R: 
5'-CAGATCCTCTTCTGAGATGAGT-3' and Akt-F: 5'-GATGAGGAGTTCACAGCT-
CAGATG-3'. Cycling conditions were: 94°C for 30 sec, followed by 35 cycles of 
amplification (94°C for 30 sec, 62°C for 30 sec, 72°C for 30 sec), with a final incubation 
at 72°C for 3 min. The final PCR products were run onto agarose gel for the detection of 
the EGFP and c-myc bands. For EGFP, the amplicon size was 315 bp and for c-myc, the 
amplicon size was 258 bp. Tails obtained from β-actin-EGFP mice and αMHC-nuc-Akt 
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mice were used as positive controls while tissue sections from animals injected with PBS 
were used as negative controls.  
Real-time RT-PCR for EGFP mRNA. This analysis was performed in infarcted mice 
treated with c-kit-BMCs obtained from αMHC-EGFP mice sacrificed at 5, 10 and 30 
days after surgery. Hearts were excised and the infarcted-regenerated area was separated 
from the spared myocardium and employed for RNA extraction. Total RNA was purified 
using RNeasy Mini kit and RNase-Free DNase Set (Qiagen) and in each sample, ~50-100 
µg of RNA were collected. RNA was eluted in 100 µl of RNase-free water, and 50 µg of 
total RNA were employed for poly(A)RNA selection using MicroPoly(A)Purist 
(Ambion). Nearly 1.5-2 µg of poly(A)RNA were recovered from each sample and treated 
with DNase I. After heat inactivation of DNase I, 500 ng of poly(A)RNA were employed 
for reverse transcription (RT) into cDNA using SuperScript III cDNA synthesis kit 
(Invitrogen); RNA was incubated with 5’-phosphorylated oligo(dT)20 primer for 3.5 
hours at 50°C. Synthesized cDNA was treated with 2 U of RNase H (Ambion) at 37°C 
for 20 minutes. Real-time RT-PCR analysis was performed on 7300 Real Time PCR 
System (Applied Biosystems) and run in duplicate using 1/20th of the cDNA per 
reaction. Approximately 25 ng of poly(A)RNA were used for non-RT control reaction.  
Primers and probes for EGFP transgene and the housekeeping gene GAPDH were 
designed from available mouse sequences using the primer analysis software Primer 
Express v2.0 (Applied Biosystems).  
The PCR-reaction included 1 μl template cDNA, 500 nM forward and reverse-
primers, and 100 nM probe conjugated with the fluorescent dye FAM in a total volume of 
25 μl. Cycling conditions were as follows: 95°C for 10 minutes followed by 50 cycles of 
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amplification (95°C denaturation for 15 sec, and 60°C combined annealing/extension 
for 1 min). FAM signal was detected at the end of each cycle. Data were analyzed using 
the Automatic Baseline of the Sequence Detection software (v. 1.2.2; Applied 
Biosystems), and the threshold was fixed at 0.05 manually for cycle threshold (Ct) 
determination. Quantified values were normalized against the input determined by the 
housekeeping mouse gene GAPDH.  
 Real-time RT-PCR products were run on 2% agarose/1x TBE gel. Amplified 
fragments were cut out and DNA was extracted using QIAquick Gel Extraction kit 
(Qiagen). DNA was eluted in 30 µl of 10 mM Tris buffer (pH 8.5), and amplified by 
Platinum Blue PCR Supermix (Invitrogen) in the presence of 260 nM of the forward and 
reverse primers utilized for real-time PCR. PCR reaction was carried out in Eppendorf 
Mastercycler. Cycling conditions were as follows: 94°C for 2 min followed by 35 
cycles of amplification (94°C denaturation for 20 sec, 60°C annealing for 30 sec, 
72°C elongation for 20 sec) with a final incubation at 72°C for 3 min. After 
purification using QIAquick PCR Purification kit (Qiagen), samples were submitted to 
the DNA Sequencing Facility at Cornell University (New York) to obtain the DNA 
sequence.  
Western blotting for EGFP and c-myc. This analysis was performed in infarcted mice 
treated with c-kit-BMCs obtained from αMHC-EGFP mice and from α-MHC-nuc-Akt 
sacrificed at 30 days after surgery. Hearts were excised and the infarcted-regenerated area 
was separated from the spared myocardium and employed for protein extraction. In each 
sample, ~10 g of proteins were collected. Equivalents of 50 μg of proteins were loaded 
for each sample. Samples were runt onto 8% polyacrylamide gels. Polyclonal rabbit anti-
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EGFP and polyclonal rabbit anti-c-myc were employed as primary antibodies at a 
concentration of 1:1,000. Anti-rabbit IgG were employed as secondary antibodies at a 
concentration of 1:3,000. EGFP was detected as a band of ~30 kDa and c-myc tag as a 
band of ~ 60 kDa.  
Myocyte contractility and calcium transients. Newly formed myocytes were isolated 
from the infarcted region of mice treated with BMCs obtained from αMHC-EGFP mice 
at 15 days. Regenerated and old myocytes were discriminated by the presence and 
absence of EGFP, respectively. Isolated myocytes obtained from the infarcted region of 
treated hearts were placed in a bath on the stage of an inverted microscope. Experiments 
were conducted at room temperature. Cells were bathed continuously with a Tyrode 
solution containing (mM): NaCl 140, KCl 5.4, MgCl2 1, HEPES 5, Glucose 5.5 and 
CaCl2 1.0 (pH 7.4, adjusted with NaOH). Measurements were performed using IonOptix 
contractility systems.  
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In vitro studies  
Isolation of BMCs and neonatal myocytes. c-kit-BMCs were isolated from wild type 
and β-actin-EGFP transgenic mice with the protocol described above. Myocytes were 
enzymatically dissociated from the heart of Sprague Dowley rats at 1 day after birth. Rats 
were decapitated and hearts were quickly removed and placed in Ca/Mg-free Hanks’ 
balanced salt solution (HBSS). The tissue was cut in small pieces, which were transferred 
into 10 ml of dissociation medium (0.1% trypsin, 1:250, and 0.01% DNase I in HBSS) 
and stirred at 37°C. The material dissociated from the tissue during the first 15 minutes of 
trypsinization was discarded. An aliquot of dissociation medium (10 ml) was added to the 
remaining fragments of myocardium, and after 10 minutes of gentle stirring at 37°C the 
supernatant was collected. The cells contained in this fraction were centrifuged at 300  g 
for 4 min, resuspended in Eagle’s MEM supplemented with 10% FBS and stored on ice. 
The procedure was repeated 4 to 6 times. Isolated cells were pre-plated in a 150-mm Petri 
dish for 1 hour at 37°C, and myocytes which did not attach to the dish during this time 
were collected10,11.  
Cell culture. C-kit-BMCs were cultured with neonatal rat myocytes in Dulbecco’s MEM 
with 10% FBS. For dye transfer studies, living cell co-cultures were analyzed by two-
photon and inverted microscopy. C-kit-BMCs were labeled with 1-2 µM of the red 
fluorescent dye DiI (Molecular Probes) for 5 min at 37°C and for 15 min at room 
temperature in Hank’s solution8. Neonatal rat myocytes were loaded with 5 µM calcein 
(Molecular Probes) for 30 min at 37°C. Cells were then washed in Ca2+/Mg2+ containing 
HBSS. Labeled c-kit-BMCs were cultured overnight in the presence of labeled neonatal 
rat cardiomyocytes. This approach was followed for the detection of functional gap 
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junctions between c-kit-BMCs and myocytes and dye transfer. The presence of green 
fluorescence in DiI-labeled cells was considered indicative of the transfer of calcein 
through gap junctions from myocytes to c-kit-BMCs. This analysis was performed by 
two-photon microscopy.  
 For real time dye transfer in co-cultured cells, c-kit-BMCs cells were loaded with 
cascade blue (1 mg/ml; Molecular Probes) by microinjection (FemtoJet, Eppendorf AG) 
of a medium containing (mM): K2HPO4, 27, NaHPO4, 8, KH2PO4, 26  (pH 7.3). 
Transfer of the fluorescent dye to neighboring cells was followed by acquisition of serial 
images. This analysis was performed using an inverted microscope. In additional 
experiments, c-kit-BMCs were loaded with rhodamine-labeled dextran (10 µg/ml). 
Statistical analysis. Results are presented as means ± SD. Differences were determined 
by the two-tailed unpaired Student’s t-test, analysis of variance and Bonferroni method6.    
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Table 1. Cell Markers, Function and Antibody Labeling 
 
Cell Markers    Function         Antibody Labeling 
 
1. BMC Epitopes and Donor Markers 
c-kit   Stem Cell Factor receptor        conjugated primary Ab 
CD45   Surface Glycoprotein          primary/secondary Ab 
CD34   HSC/EC antigen          conjugated primary Ab 
CD45   Pan-myeloid marker          conjugated primary Ab 
CD45RO  T-lymphocyte subset marker         conjugated primary Ab 
CD8   T-lymphocyte subset marker         conjugated primary Ab 
CD20   B-lymphocyte marker          conjugated primary Ab 
TER-119  Erythroid marker          conjugated primary Ab 
 
2. Donor BMC Markers 
EGFP   Fluorescent protein         conjugated primary Ab 
c-myc   Tag sequence of Akt transgene       conjugated primary Ab  
 
3. Junctional Proteins 
Connexin 45   Engraftment of BMCs         conjugated primary Ab 
N-cadherin  Engraftment of BMCs         conjugated primary Ab  
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 4. Transcription Factors of Cardiac Cell Lineages 
GATA-4  Differentiation of cardiac cells       conjugated primary Ab 
Nkx2.5  Differentiation of cardiomyocytes        conjugated primary Ab  
MEF2C  Differentiation of cardiomyocytes       conjugated primary Ab 
GATA-6  Differentiation of VSMCs        conjugated primary Ab 
Ets1   Differentiation of ECs        conjugated primary Ab 
 
5. Structural Proteins of Cardiac Cell Lineages 
α-sarcomeric actin Contractile protein of cardiomyocytes      conjugated primary Ab 
α-actinin  Contractile protein of cardiomyocytes      conjugated primary Ab  
Cardiac myosin Contractile protein of cardiomyocytes      conjugated primary Ab 
α-SM actin  Contractile protein of VSMCs        conjugated primary Ab 
Von Willebrand  Factor VIII receptor in ECs         conjugated primary Ab 
Factor 
Vimentin  Intermediate filament in ECs and Fs        primary/secondary Ab 
 
6. Cell Proliferation  
BrdU   S-phase marker          primary/secondary Ab 
MCM5  cell cycle protein          primary/secondary Ab 
Ki67   cell cycle marker          primary/secondary Ab 
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BMCs: Bone Marrow Cells; VSMCs: Vascular Smooth Muscle Cells; ECs: Endothelial 
Cells; Fs: Fibroblasts; Ab: Antibody. 
 
Sources of Antibodies: Dako: c-kit, CD45, CD45RO, CD8; Molecular Probes: EGFP; 
Pharmingen: TER-119; Roche: BrdU; Santa Cruz: GATA-4, MEF2C, GATA-6, Ets1, 
N-cadherin, MCM5, CD34, CD20; Sigma: α-sarcomeric actin, connexin 43, α-smooth 
muscle actin, von Willebrand factor, vimentin; Upstate Biotechnolegy: c-myc tag; 
Vector Laboratories: Ki67;  
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